Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Cell Therapeutics Company Profile (NASDAQ:CTIC)

Consensus Ratings for Cell Therapeutics (NASDAQ:CTIC) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $4.83 (82.39% upside)

Analysts' Ratings History for Cell Therapeutics (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetDetailsShare
5/22/2014Ladenburg ThalmannInitiated CoverageBuy$6.00ViewTweet This Rating  Share This Rating on StockTwits
3/19/2014WallachBeth CapitalInitiated CoverageHold$4.50ViewTweet This Rating  Share This Rating on StockTwits
11/4/2013HC WainwrightInitiated CoverageBuy$4.00ViewTweet This Rating  Share This Rating on StockTwits
10/29/2013Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
10/7/2013Wells Fargo & Co.Reiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
10/26/2012Roth CapitalInitiated CoverageBuy$4.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2012ThinkEquityInitiated CoverageBuy$3.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2012 forward)